News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Revenue from operations up 26% to Rs. 768 crores
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
The company increases its efficiency and is able to face the growing demand for its services.
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Transformation to pure-play Innovative Medicines company nears completion
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Subscribe To Our Newsletter & Stay Updated
